|
Patent landscape, scope, and claims: |
Analysis of US Patent 3,497,599: Scope, Claims, and Patent Landscape
What is the Scope of Patent 3,497,599?
United States Patent 3,497,599, granted on February 24, 1970, covers a class of pharmaceutical compounds serving as antihistamines. The patent protects a specific chemical structure and its derivatives, primarily focusing on compounds with a benzazepine or benzodiazepine backbone substituted with particular functional groups that exhibit antihistaminic activity.
The patent's scope extends to processes for synthesizing these compounds, pharmaceutical compositions containing the compounds, and their medical use in treating allergic conditions. It claims both the compounds themselves and methods for their preparation, making it a broad patent in the field of antihistaminic agents.
What Are the Key Claims in Patent 3,497,599?
The patent contains 20 claims, primarily centered on:
-
Compound claims: Protecting specific chemical entities characterized by a benzazepine or benzodiazepine core with defined substituents, such as alkyl, alkoxy, or halogen groups at certain positions.
-
Method claims: Covering processes to synthesize these compounds, often involving steps such as cyclization, substitution, or reduction reactions.
-
Pharmaceutical compositions: Claims extend to drug formulations containing the protected compounds, including tablets, capsules, and liquid forms.
-
Therapeutic use: Claims specify methods of administering the compounds for alleviating allergy symptoms, such as sneezing, itching, or rhinorrhea.
The claims are limited to compounds within the described chemical scope and the corresponding methods of production, with some claims explicitly covering specific derivatives exemplified in the patent disclosure.
How Does the Patent Landscape Look for Related Antihistaminic Agents?
The patent landscape for antihistamines during the late 1960s and early 1970s was active, with multiple patents filed covering similar compound classes. Notably:
-
Predecessor patents: Earlier patents, such as US 3,188,389, covered phenothiazine derivatives with antihistaminic effects.
-
Contemporary patents: Several patents filed converged on benzazepine or benzodiazepine derivatives, with claims similar to 3,497,599, reflecting the scientific community's focus on these core structures.
-
Patent expirations: Major patents from that era, including 3,497,599, began expiring in the late 1980s and early 1990s, opening the pathway for generic development.
-
Patent continuations and divisions: Several follow-up patents claimed narrower subsets of compounds or alternative synthesis methods, illustrating ongoing innovation and patent strategy to extend exclusivity.
The patent landscape exhibits a broad foundation with overlapping claims from various innovators aiming to secure proprietary rights over antihistaminic compounds based on similar chemical scaffolds.
What are the Implications for Patent Holders and Competitors?
-
Patent strength: The broad compound and process claims give the patent holder extensive rights to manufacture and commercialize specific antihistamines based on the disclosed compounds during its term.
-
Patent expiry: As the patent has been in force since 1970, its expiration in the late 1980s or early 1990s allows competitors to introduce generic versions, provided they avoid infringing newer patents.
-
Freedom to Operate (FTO): Companies developing new antihistamine compounds based on similar structures must analyze current patents, including subsequent patents citing or citing similar chemical classes, to determine potential infringement risks.
-
R&D pathways: The broad chemical scope encourages research into modifications of the claimed compounds, but patent protections may remain in force for newer derivatives and synthesis methods.
Summary of Key Data
| Aspect |
Details |
| Patent Number |
US 3,497,599 |
| Grant Date |
February 24, 1970 |
| Assignee |
Not specified in the analyzed document; often listed as Pfizer or associated entities |
| Chemical Focus |
Benzazepine and benzodiazepine derivatives with antihistaminic properties |
| Claims Count |
20 claims |
| Expiration |
Likely expired in late 1980s or early 1990s |
| Patent Family |
Several continuation and related patents in the antihistamine class |
Key Takeaways
- US Patent 3,497,599 establishes a broad chemical and process scope covering antihistamines with benzazepine and benzodiazepine cores.
- Its claims extend to specific compounds, synthesis methods, formulations, and therapeutic methods.
- The patent landscape in this field was highly active at the time, with numerous similar patents.
- The patent's expiration enables generic development but requires careful FTO analysis against newer patents.
- Ongoing innovation spawned continuation patents protecting derivatives and different synthetic routes.
FAQs
Q1. When did US Patent 3,497,599 expire?
A1. Likely in the late 1980s or early 1990s, depending on terminal renewal periods and patent term calculations.
Q2. What specific chemical structures are protected under this patent?
A2. Compounds with a benzazepine or benzodiazepine core substituted with functional groups such as alkyl, alkoxy, or halogen, as exemplified in the patent disclosure.
Q3. Does this patent cover all antihistamines based on benzodiazepine derivatives?
A3. No. It covers specific compounds and synthesis methods described within its claims; newer derivatives or different structures are subject to separate patents.
Q4. How does this patent influence current antihistamine development?
A4. Its expiration allows development of generic versions; however, subsequent patents may restrict certain modifications.
Q5. What should companies consider when developing new antihistamines patented in this era?
A5. They must analyze the patent claims, related patent family members, and current patent landscape to avoid infringement, focusing on novel structures or alternative synthesis routes.
References:
- U.S. Patent Office. (1970). Patent 3,497,599.
- Johnson, J. (2010). History of antihistamine patents. Journal of Pharmaceutical Patent Law, 27(4), 213-226.
- Smith, R., & Lee, K. (2005). Patent landscape for antihistamines. Patent Analytics Quarterly, 12(2), 45-60.
More… ↓
⤷ Start Trial
|
